Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Journal
Liver cancer
Journal Volume
11
Journal Issue
1
Date Issued
2022-01
Author(s)
Rimassa, Lorenza
Kelley, Robin Kate
Meyer, Tim
Ryoo, Baek-Yeol
Merle, Philippe
Park, Joong-Won
Blanc, Jean-Frederic
Lim, Ho Yeong
Tran, Albert
Chan, Yi-Wah
McAdam, Paul
Wang, Evelyn
El-Khoueiry, Anthony B
Abou-Alfa, Ghassan K
Abstract
Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this exploratory analysis, outcomes were evaluated according to plasma biomarker levels.
Subjects
Cabozantinib; Hepatocellular carcinoma; Plasma biomarkers; Prognostic factors
Publisher
KARGER
Type
journal article